Listar por tema "WARFARIN"

Cost-Minimisation Analysis of Oral Anticoagulant Therapy Monitoring Methods: The Case for Prothrombin Time Self-Monitoring

Geitona, M.; Hollandezos, M.; Souliotis, K.; Athanasakis, K.; Kyriopoulos, J. (2008)

Introduction: Anticoagulant therapy is usually chronic and is indicated for the treatment of several medical conditions. The most common of these include patients with mechanical heart valves and those suffering from atrial ...

Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ntaios, G.; Papavasileiou, V.; Diener, H. C.; Makaritsis, K.; Michel, P. (2012)

Background and Purpose-To assess whether the combined analysis of all phase III trials of nonvitamin-K-antagonist (non-VKA) oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic ...

Re: 'Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'

Spanos, K.; Giannoukas, A. D. (2015)

Restarting oral anticoagulants after intracerebral hemorrhage: pros

Ntaios, G. (2015)

A systematic review of cost effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

Verhoef, T. I.; Redekop, W. K.; Darba, J.; Geitona, M.; Hughes, D. A.; Siebert, U.; de Boer, A.; Zee, Ahmvd; Grp, Eu-Pact (2010)

Anticoagulant therapy with coumarin derivatives is often sub- or supra-therapeutic, resulting in an increased risk of thromboembolic events or hemorrhage, respectively. Pharmacogenetic-guided dosing has been proposed as ...